In the DESTINY-Lung01 trial, T-DXd at 6.4 mg/kg yielded an ORR of 55%, a median DoR of 9.3 months, and a median PFS of 8.2 months in pretreated HER2-mutant NSCLC.27 In the subsequent DESTINY-Lung02 trial, T-DXd at 6.4 mg/kg and the approved dose of 5.4 mg/kg showed ORRs of 56.0% and 49.0%, and DoRs of not reached and 16.8 months respectively for HER2-mutant NSCLC.27,28 SHR-A1811 at the RP2D of 4.8 mg/kg showed generally similar efficacy with T-DXd at 5.4 mg/kg in HER2-mutant NSCLC, with an ORR of 41.9%, a durable DoR of 13.7 months (not mature), and PFS of 8.4 months. This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.